Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 191Thoracic 59Head & Neck 24Gynecologic 10Lymphoid 9Breast 9CNS 6Tumor-Agnostic 4Genitourinary 4Sarcoma 3Endocrine 3Other solid neoplasm 2Other neoplasm 2NET 2Myeloid 1Dermatologic 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1

Interventions

Cyclophosphamide 229fludarabine phosphate 206fludarabine 163Busulfan 150Mycophenolic Acid 135Tacrolimus 133Whole-Body Irradiation 132Peripheral Blood Stem Cell Transplantation 121Cytarabine 101Azacitidine 100Antilymphocyte Serum 98Melphalan 96Cyclosporine 96Methotrexate 87Imatinib Mesylate 87Filgrastim 85Decitabine 66Granulocyte Colony-Stimulating Factor 60Thiotepa 57venetoclax 53Stem Cell Transplantation 53thymoglobulin 51Radiotherapy 49Cord Blood Stem Cell Transplantation 42nilotinib 40Clofarabine 38Dasatinib 37Methylprednisolone 36ruxolitinib 35Etoposide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × sintilimab × Myeloid × Clear all
NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Sun Yat-sen University

Phase 2 Unknown
37 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡